Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer

Prostate‐specific antigen (PSA)‐based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves overdetection of low‐risk disease with potential adverse effects. We evaluated PCa incidence among men with PSA below 3 ng/mL and no PCa diagnosis at the first screening round of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ola, Idris Olasunmbo, Talala, Kirsi, Tammela, Teuvo, Taari, Kimmo, Murtola, Teemu, Kujala, Paula, Raitanen, Jani, Auvinen, Anssi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Cancer Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087780/
https://www.ncbi.nlm.nih.gov/pubmed/36056577
http://dx.doi.org/10.1002/ijc.34274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087780/
https://www.ncbi.nlm.nih.gov/pubmed/36056577
http://dx.doi.org/10.1002/ijc.34274

Ejemplares similares